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Decreasing incidence of registered 
hydatidiform moles in Denmark 
1999–2014
Helle Lund1,2*, Mogens Vyberg1,2, Helle Højmark Eriksen3, Anni Grove1, 
Annette Østergaard Jensen1 & Lone Sunde4,5
Incidences of hydatidiform mole (HM) registered in European countries varies from 0.98/1000 to 
2.17/1000 deliveries, while higher incidences have been reported in other parts of the world. We 
calculated the incidence by selecting data on HMs classified as ”first”, “second” and “third” from 
01.01.1999 to 31.12.2014 registered in the Danish Pathology Registry, which we previously showed 
to be the most complete data source on the number of HMs in Denmark. In the study period, 1976 
first HMs were registered; 1080 (55%) were classified as PHMs (partial HMs) and 896 (45%) as NPHMs 
(HMs not registered as PHMs). The average incidence of HM was 1.98/1000 deliveries. The incidence of 
PHM was 1.08/1000 deliveries and the incidence of NPHM was 0.90/1000 deliveries. Forty HMs were 
registered as second HMs; 85% (34/40) were of the same histopathological type as the first HM. The 
registered incidence of HM decreased from 2.55/1000 deliveries in 1999 to 1.61/1000 deliveries in 2014 
(p < 0.005). The decrease in the incidence of HM was identical with a decrease in the incidence of PHM. 
New medical practices such as medical abortion and only forwarding selected pregnancy products for 
histopathologic examination may cause a declining number of HMs registered.
Hydatidiform mole (HM) is an abnormal human pregnancy and the most common gestational trophoblastic 
disease. Based on morphological criteria, HMs can be classified as complete hydatidiform moles (CHM) or partial 
hydatidiform moles (PHMs)1. HM is a rare cause of miscarriage, but a frequent cause of gestational trophoblastic 
 neoplasia2. HMs have been recognized for more than 1000 years3. In Europe, the reported incidence of HM var-
ies from 0.98 to 2.17 per 1000 deliveries in the period 1997–2013, while higher incidences have been reported 
from other parts of the  world4–9.
Several factors limit the accuracy of the incidences estimated. First and foremost, we know little about very 
early pregnancies. Some molar conceptuses may vanish before the pregnancy is recognized. And similarly, we 
do not know the correct denominator, as the total number of pregnancies in a population can only be estimated 
with uncertainty. Therefore various “surrogate denominators” are being used, such as “number of viable preg-
nancies” and “number of deliveries”. In addition many reports concern the observations in a hospital, a referral 
center, or similar, introducing a risk of referral  bias9–11. Furthermore, the accuracy of the incidences estimated 
will be influenced by other factors, such as the ability to uniquely identify each individual in a population and 
the completeness of the registries used.
In Denmark, each individual is unambiguously identifiable due to the civil personal registration (CPR) num-
ber, assigned at birth or immigration. Systematic registration of births in Denmark started in  196812, and since 
2006 the number of induced abortions and miscarriages has been registered in the Danish Database for Early 
Pregnancy and Abortion (TiGrAb, se description below). Further, women with a HM are registered in three 
governmental registries: the Danish National Patient  Registry13, the Danish Cancer  Registry14, and the Danish 
Pathology Registry (DPR)15. We recently proved the DPR to be the most complete data source for research on 
the number of HMs in  Denmark16. Here we present the incidence of HM in Denmark for the period 1999–2014, 
estimated from data in the DPR. We also review the incidences estimated in other population-based stud-
ies published in the period 01.01.1990–31.12.2019. The average incidence of registered HMs in Denmark was 
among the highest reported incidences in Europe. Further, we observed a significantly decreasing incidence of 
PHM over time.
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Methods
We conducted a population-based study in Denmark (approximately 5.5 million inhabitants). The entire popu-
lation receive tax-supported health care from the Danish National Health Service without out-of-the-pocket 
expenses for hospital care. Since 1968, the Danish Civil Registration System has kept up-to-date electronic records 
on the date of birth, gender and changes in vital status for all Danish residents. Each resident in Denmark is 
assigned a unique 10-digit CPR number, which allows unambiguous linkage among Danish  registries17.
The Danish Pathology Registry. The DPR holds nationwide data on pathology investigations and is 
managed by the Danish National Board of Health. The DPR was established in 1997, however computer-based 
recording of pathological specimens was initiated in Denmark in the 1970s. Since 1999, reporting to the DPR 
automatically takes place through the Danish Pathology Data Bank, a nationwide database working as a rou-
tine online tool for all pathology departments in  Denmark18. For each specimen, data on the patient, date of 
registration, gross and microscopy descriptions, and diagnoses are registered. Coding is performed using the 
Danish modification of the Systemized Nomenclature of Medicine (SNOMED, https ://www.patob ank.dk/index 
.php?ID=4&lang=da). The data quality is ensured by the approval of all diagnostic statements in the pathology 
report by a pathologist, and a debugging system that ensures that all reports are given at least one code for topog-
raphy and one code for morphology. The registration in the DPR is performed on-line as an automated function 
linked to the electronic sign out of a pathology report.
Identification of hydatidiform moles. In the DPR, data are registered for each specimen analyzed. Ini-
tially we retrieved data on all specimens registered with a SNOMED morphology code for HM in the DPR from 
01.01.1987 to 31.12.2014. In this data set, each specimen was listed with the CPR number of the woman and the 
date of registration in the DPR, along with a number of other variables. We grouped the specimens according 
to the CPR number. In each group, we identified the woman’s first HM by the CPR number and the first date 
of registration of a specimen. Further, in each group, all specimens registered 0–180 days after the first date of 
registration were ignored, whereas a specimen with the earliest date of registration later than 180 days after the 
first date of registration was identified as a second HM. A third HM was identified by the CPR number and the 
earliest date of registration more than 180 days after the date of registration of a second HM, and so on.
To estimate the incidence of HM in the period 01.01.1999–31.12.2014, we selected data on HMs classified as 
“first HMs” with a date of registration in this period. To calculate the frequency of subsequent HMs in the period 
01.01.1999–31.12.2014, we selected data on HMs classified as “second HMs” or “third HMs” in the period. No 
HMs were classified as “fourth HMs”.
Throughout the period 01.01.1987–31.12.2014, the SNOMED morphology code M91030 has been used for 
“partial hydatidiform mole” (Table 1). The code M91000 was used for “hydatidiform mole” until 31.12.2013 and 
for “complete hydatidiform mole” thereafter. The code M910A0 for “hydatidiform mole, not otherwise specified” 
was introduced in 01.01.2014. The code ÆYYY00 is a moderator code indicating “suspicion of ”. The moderator 
code can be used as a supplement to the morphology codes.
We defined two groups of HMs: HMs encoded M91030 were defined as PHMs (partial HMs), and HMs 
encoded M91000 or M910A0 were defined as NPHM (HMs, not registered as PHMs).
The Danish Medical Birth Registry. We retrieved the total number of deliveries from the Danish Medi-
cal Birth Registry (MBR), which was established in 1968 and computerized in  197312. The MBR is a national 
health registry. In 1997, electronic registration of births from the Danish National Patient  Registry13 replaced 
the previously used paper  forms19. The registry contains information on both live births and stillbirths. Before 
01.01.2005, a pregnancy which concluded at a gestational age of 28 weeks or later, was considered as resulting in 
a birth. From 01.01.2005 a pregnancy, which concluded at a gestational age of 22 weeks or later, was considered 
as resulting in a birth.
The Danish Database for Early Pregnancy and Abortion. We retrieved the number of induced 
abortions, miscarriages, ectopic pregnancies, and pregnancies of unknown localization from the data-
base TiGrAb (The Danish Database for Early Pregnancy and Abortion; https ://www.sundh ed.dk/conte nt/
cms/67/4667_%C3%A5rsr appor t-2016_endel ig_anony miser et.pdf). The database is a clinical quality database 
managed by the National Board of  Health20. TiGrAb was established in 2006 and the content is based on data 
from the Danish National Patient  Registry13.
Table 1.  SNOMED codes for hydatidiform mole in the Danish Pathology Registry 1999–2014.
Code Period Diagnosis
M91000 01.01.1999–31.12.2013 Hydatidiform mole
M91000 01.01.2014–31.12.2014 Complete hydatidiform mole
M910A0 01.01.2014–31.12.2014 Hydatidiform mole, not otherwise specified
M91030 01.01.1999–31.12.2014 Partial hydatidiform mole
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17041  | https://doi.org/10.1038/s41598-020-73921-4
www.nature.com/scientificreports/
Statistical analyses. The incidence of HM per delivery was calculated as the number of first HMs regis-
tered in the DPR in the period 01.01.1999–31.12.2014 divided by the total number of deliveries registered in the 
MBR in the same period. To evaluate the association between the incidence of HM and age, we stratified the data 
according to the maternal age at the date of registration of the specimen. For the period 01.01.2007–31.12.2014, 
the number of pregnancies was available. We calculated the incidence per pregnancy by dividing the number of 
first HMs registered in the DPR in the period 01.01.2007–31.12.2014 by the total number of pregnancies ending 
in the same period. The total number of pregnancies was calculated by adding the number of deliveries (retrieved 
from the MBR) and the number of HMs (identified in the DPR) to the number of induced abortions, miscar-
riages, ectopic pregnancies, and pregnancies of unknown localization retrieved from TiGrAb (Supplementary 
material, part A). Poisson regression model (Wald test) was used to compare incidence rates. Statistical analyses 
were performed with STATA software (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP). The study was registered at the Danish Data Protection Agency (record no 2014-41-3541).
Literature search. To identify incidences of HM reported from population-based studies, we identified lit-
erature in PubMed by searching for “molar pregnanc*” or “hydatidiform” or “gestational trophoblastic disease*” 
in the title, and “incidence*” in the title or abstract, for papers published in the period 01.01.1999–31.12.2019. 
The initial search in PubMed resulted in 194 references. By reading the title, abstract, and if necessary the text, 
the following studies were excluded; review articles, hospital-based studies, institution-based studies, multi-
center-studies, and studies from referral centers, as well as studies in non-English language and studies for which 
details on data source and data management were missing.
Results
A total of 1976 first HMs were registered in the period 01.01.1999–31.12.2014; 896 (45%) first HMs were classified 
as NPHMs and 1080 (55%) were classified as PHMs. From 01.01.2014 to 31.12.2014, 34/91 (37%) first HMs were 
registered as CHMs, 55/91 (60%) were registered as PHMs, and two (2%) were registered as “hydatidiform mole, 
not otherwise specified” (M910A0). The moderator code indicating “suspicion of ” was used in 277 of 1976 first 
HMs (14%); in 117/896 (13%) of the first HMs classified as NPHMs and in 160/1080 (15%) of the first HMs 
classified as PHMs (Supplementary material, part B). There was no significant change in the proportion of HMs 
registered with the moderator code indicating “suspicion of ” over time (data not shown).
The mean age of women registered with a first HM classified as a NPHM was 30 years, range 13–56 years; 
and the mean age of women registered with a first HM classified as a PHM was 30 years, range 14–60 years.
According to the DPR, the average incidence of HM from 1999 to 2014 was 1.98/1000 deliveries (Supple-
mentary material, part B). The incidence of HM classified as NPHM was 0.90/1000 deliveries. The incidence of 
HM classified as PHM was 1.08/1000 deliveries. By excluding all first HMs with the moderator code, the fol-
lowing minimum average incidences were calculated: HM: 1.70/1000 deliveries, NPHM: 0.78/1000 deliveries, 
and PHM: 0.92/1000 deliveries. The incidence of HM decreased from 2.55/1000 deliveries in 1999 to 1.61/1000 
deliveries in 2014 (p < 0.005). The decrease occurred mainly in the first part of the period (Fig. 1). The decrease 
in the incidence of HM was almost identical to a decrease in the incidence of PHM. The decrease in the incidence 
of PHM was also significant (p < 0.005). No significant change over time was observed for NPHM (p = 0.12).
The highest incidence of HM was observed in women younger than 20 years (10.52/1000 deliveries) and 
in women older than 39 years (5.95/1000 deliveries). The tendency for higher incidences among both young 
and elderly women was more pronounced for NPHM than for PHM (Fig. 2). However, the absolute number of 
HM was highest for women between 20 and 39 years (1657/1976, 84%). The proportion of NPHMs in women 
Figure 1.  Incidence of hydatidiform mole (HM) in Denmark 1999–2014. NPHM HM registered with the code 
M91000 (hydatidiform mole or complete hydatidiform mole) or M910A0 (hydatidiform mole, not otherwise 
specified); PHM HM registered with the code M91030 (partial hydatidiform mole).
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younger than 20 years and in women older than 39 years was 59% and 62%, respectively, while it was 42% in 
women 20–39 years old.
In the period 2007–2014, the average incidence of HM was 1.23 per 1000 pregnancies with no obvious change 
over time (Supplementary material, part C).
In the period 01.01.1999–31.12.2014, 40 second HMs and one third HM were registered. No fourth HM 
was registered. Thirty-four of the 40 second HMs (85%) were of the same histopathological type as the first 
HM; 22 second HMs were PHMs and 18 second HMs were NPHMs (Table 2). In 16/16 women registered with 
a second HM whose first HM was a PHM, the second HM was also a PHM. Twenty-four of 896 (2.7%) women 
whose first HM was a NPHM, were also registered with a second HM, whereas 16 of 1080 (1.5%) women whose 
first HM was a PHM, were registered with a second HM. The median interval between the first and second HM 
was 582 days (Supplementary material, part D). The third HM was a NPHM, and both the first and second HM 
in this woman were NPHMs. For women having a second HM, the mean age at which the women experienced 
their first HM was 30 years (range 15–56), and 28 years (range 24–37), respectively, in women where the first 
HM was a NPHM and a PHM, respectively. The woman with a third HM was 23 years old, when the first HM 
was registered.
Searching the literature for studies reporting the incidences of HM estimated in population-based studies, we 
identified 17 papers published in 1990–2019 (Table 3). Most studies were from European countries, no studies 
were from Africa, South America, or Australia.
In ten studies the incidence per pregnancy or viable conception was estimated, and in 13 studies the incidence 
per delivery or live birth was estimated. Furthermore, the four denominators indicated were defined in differ-
ent ways, or undefined. One example: Among the ten studies reporting incidence per delivery, in five studies 
delivery was defined in four different ways, and in five studies delivery was not defined (Table 3). Nine studies 
reported the incidence per delivery/live birth for more than one period and five studies reported the incidence 
per pregnancy/viable conception for more than one period (Figs. 3 and 4). 
Discussion
We estimated the incidence of HM in Denmark using the DPR, a nation-wide registry with a high completeness, 
and a high concordance between the description in the pathology report and the SNOMED  code16. Among the 
strengths of our study is the population-based design applied in Denmark, where citizens have equal access to 
health care. Furthermore, unique identification of individuals was possible as CPR numbers are assigned to all 
Figure 2.  Age specific incidence of hydatidiform mole (HM) in Denmark 1999–2014. NPHM HM registered 
with the code M91000 (hydatidiform mole or complete hydatidiform mole) or M910A0 (hydatidiform mole, not 
otherwise specified); PHM HM registered with the code M91030 (partial hydatidiform mole).
Table 2.  Frequency and morphological subtype of the second hydatidiform mole (HM) stratified on 
morphological subtype of the first HM (NPHM or PHM). HM hydatidiform mole, NPHM a HM not registered 
as a PHM, PHM partial hydatidiform mole. a HM registered with the code M91000 (hydatidiform mole or 
complete hydatidiform mole) or M910A0 (hydatidiform mole, not otherwise specified). b HM registered with 
the code M91030 (partial hydatidiform mole).
First HM
Second HM
Total HMs registeredNPHMa PHMb Total
NPHMa 18 6 24 896
PHMb 0 16 16 1080
Total 18 22 40 1976
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Author (year) Population Data source N/R Period No
Incidence per 1000 total (complete HM/partial HM)
Pregnancies Viable conceptions* Deliveries Live births
Scandinavia
Present study Denmark The Danish Pathology Registry N
1999–2014 1976 1.98 (0.9a/1.08)
2007–2014 863 1.23 (0.61a/0.62) 1.79
Olsen et al.37 Denmark
The Danish National 
Patient Registry/
The Danish Cancer 
Registry
N 1977–1992 1520 1.1b
Salehi et al.26 Sweden
The Swedish Cancer 
Register/The 
Inpatient Register
N 1973–2004 3844 1.2c
Joneborg et al.5 Stockholm County, Sweden
The Regional 
Cancer Register of 
Stockholm County/
The Regional 
Pathology data base
R 1991–2010 956 1.48d 2.08e
Flam et al.36 Stockholm County, Sweden
The Regional 
Cancer Register of 
Stockholm County/
medical records
R 1975–1988 393 0.9f 1.5
Loukovaara et al.4 Finland
The hospital 
discharge registry 
of the National 
Research and 
Development Center 
for Welfare and 
Health
N 1975–2001 1659 0.98
Europe
Savage et al.34 England and Wales
Databases of the 
Trophoblastic 
Disease Centres 
at Charing Cross 
Hospital (London) 
and Weston Park 
Hospital (Sheffield)
N 2000–2009 13,583 1.65g (0.70/0.95) 2.13h
Savage et al.27 England and Wales
Databases of the 
Trophoblastic 
Disease Centres 
at Charing Cross 
Hospital (London) 
and Weston Park 
Hospital (Sheffield)
N 1998–2007 14,161 1.69i 2.17h
Tham et al.33 Northern England and North Wales
The Trophoblastic 
Screening and 
Treatment Centre, 
Weston Park Hospital 
(Sheffield)
R 1991–1999 3637 1.38
Eysbouts et al.6 The Netherlands A national pathology database, PALGA N 1994–2013 5135 1.36 (0.52/0.67)
Lybol et al.11 The Netherlands A national pathology database, PALGA N 1995–2008 3668 1.34 (0.47/0.69)
Parazzini et al.25 Lombardy, Northern Italy
Integrated Patients 
Database of the 
Lombardy Region
R 1996–2008 1433 1.04j
USA/Canada
Altman et al.8 Nova Scotia, Canada
Nova Scotia 
Gestational 
Trophoblastic 
Disease Registry
N 1990–2005 420 2.20k (0.71/1.45) 2.64l (0.93/1.71) 2.66 (0.94/1.72)
Smith et al.32 New Mexico, USA The New Mexico Tumor Registry N 1988–1997 389 1.20
m (0.81/0.39) 1.42 (0.96/0.46)
Asia
Yuk et al.22 South Korea
National Inpatient 
Sample, extracted 
records of 13% of 
patient per year
N 2009–2015 285 1.10n (0.10/0.10)
Kim et al.7 Korea Korea medical insurance system N 1991–1994 5855 2.05
Continued
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Author (year) Population Data source N/R Period No
Incidence per 1000 total (complete HM/partial HM)
Pregnancies Viable conceptions* Deliveries Live births
Matsui et al.23 Chiba Prefecture, Japan
Questionnaires 
registration system R 1985–2002 1876 1.  5
o (0.83/0.67)
Matsui et al.24 Chiba Prefecture, Japan
Questionnaires 
registration system R 1974–2000 3778 2.27
Table 3.  Incidence of hydatidiform mole (HM) reported in population-based studies since 1990. N/R: N, 
National studies concerned one country (for USA/Canada: one state/province). R, Regional studies concerned 
one well-defined region. No: Number of hydatidiform moles. *Incidences listed here where either referred 
to as “viable conceptions” and/or it appeared that miscarriages were not included in the denominator. a HM 
not registered as PHM. b Pregnancies: live births, stillbirths, induced abortions, and spontaneous abortions. 
c Deliveries: live births and stillbirths from gestational age 28 or later. d Viable conceptions: deliveries and 
pregnancy terminations. e Deliveries: live births and stillbirths (multiple births counted as one delivery). 
f Pregnancies: spontaneous, missed, and legal abortions, ectopics and deliveries. g Conceptions: live births, 
stillbirths, terminations and moles. h Maternities: live births and stillbirths. i Conceptions: live births, stillbirths, 
terminations, and moles. j Pregnancies: births, spontaneous or induced abortions, ectopic pregnancies 
and hydatidiform moles. k Pregnancies: live births, stillbirths, induced abortions, miscarriages and ectopic 
pregnancies. l Deliveries: live births and stillbirths 20 or more weeks of gestational age. m Pregnancies: live 
births, fetal deaths (stillbirths of > 20 weeks of gestational age or 500 g) and induced abortions (not first 
trimester abortion or ectopic pregnancies). n Pregnancies: GTD cases, ectopic pregnancies, abortions and 
deliveries. o Pregnancies: live births, stillbirths and therapeutic abortions.
0
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Figure 3.  Trends in the incidence of hydatidiform mole (HM) from population-based studies in the period 
1990–2019 calculated per 1000 deliveries, maternities or live births.
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Danish citizens. Lastly, to optimize the accuracy of the estimated number of first HMs from 1999 to 2014, we 
used data for the period 1987–1998 to exclude as many women as possible with a previous HM in that period.
Inherent in a study like this, is the limitation that data on very early spontaneous abortions and medical abor-
tions, are not registered. Also, as the code M91000 was used for “hydatidiform mole” in the period 1999–2013, 
we were not able to tell which of the HMs encoded M9100 before 2014 were CHMs, and which were HMs that 
were not specified. However, data from 2014 suggest that most HMs encoded M91000 were CHMs. We did not 
look into the ethnic origin of the women. However, the number of immigrant women in Denmark is expected 
to be  low21. Finally, we cannot exclude that the frequency of subsequent HMs is overestimated as it was not pos-
sible to ensure complete gonadotropin remission before diagnosing second or third HMs or underestimated as 
registration of HMs before 1998 may have been less complete than after.
We calculated the incidence as the number of first HMs registered in the DPR in a given period, divided by the 
number of deliveries or pregnancies terminated in the same period. Using the total number of specimens given 
a HM code in the DPR could lead to an overestimation of the incidence of HM, as re-evacuation is performed 
in some women having had a HM. On the contrary, using the number of women registered in the DPR with a 
first HM, only, would result in an underestimation of the frequency of HM, as a woman can have more than one 
HM. To address the latter, we calculated the frequency of subsequent HMs as well.
For the period 1999–2014, we observed a decrease in the incidence of HM registered in Denmark, most 
pronounced for the first part of the period. Several studies have reported decreasing incidences of HM in 
 Asia22–24. In contrast, since 1990 this has only been reported once from Europe: In the Lombardy region of Italy 
the registered incidence of HM per pregnancy decreased from 1996 to 2008, tentatively explained by the authors 
by a decreasing incidence among Asian women residing in the  region25.
Most European studies describe an increase in the incidence of HM per delivery over time (Fig. 3) and in 
most papers it is speculated, that the increasing incidence could be due to an increased use of ancillary diagnostic 
 techniques5,6,11,26,27. Immunohistochemical staining of p57, in situ hybridization, flow cytometry, and genotyping 
are useful ancillary techniques in the diagnostics of HMs and may lead to an increased number of conceptuses 
diagnosed as HMs. However, the increased use of ancillary techniques may also result in a decrease in the 
observed incidence, as some suspected HMs can be ruled out as moles. We did not observe any change over 
time in the proportion of HMs registered with the moderator code indicating “suspicion of ”, suggesting that the 
frequency of conceptuses with a mole(-like) phenotype that is not diagnosed with certainty, has not changed 
significantly during the period.
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Figure 4.  Trends in the incidence of hydatidiform mole (HM) from population-based studies in the period 
1990–2019 calculated per 1000 pregnancies or conceptions.
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The decreasing incidence of registered HMs in Denmark could possibly be explained by the gynecologists 
sending fewer products of conception for histopathological examination due to the increased use of medical 
abortions for both induced and missed  abortions28. In early pregnancy failures, histological examination remains 
the gold standard for diagnosing HMs, as routine pre-evacuation ultrasound examination identifies less than 
50% of HMs, the majority sonographically appearing as missed abortion or incomplete  miscarriage29. From 2001 
to 2016 the fraction of Danish women with spontaneous abortion having evacuation decreased from 22.8% to 
5.9%. Likewise, the fraction of women with missed abortion having evacuation decreased from 71.7% to 42.5%30. 
Although the risk of persistent trophoblastic disease is low following a  PHM2, it is very important that all prod-
ucts of conception with a suspicion of a HM, are sent for histopathological examination.
Due to the risk of referral bias in hospital-based studies, incidences are preferably estimated in population-
based  studies9–11. These can be either regional, concerning a well-defined region, or national, concerning an entire 
country, state, or province. However, even from population-based studies, quite varying incidences have been 
reported. In a nationwide study from Nova Scotia, an average incidence of 2.64/1000 deliveries in 1990–2005 
was observed (Table 3). No information about time trend was  given8. Also, two region-based studies from Asia 
reported higher average incidences than the Danish incidence: 2.27/1000 live births in Japan (1974–2000) and 
2.05/1000 deliveries in Korea (1991–1994)7,24. This may be an indication that ethnicity is a risk factor for molar 
 pregnancies31–33. However, as our study period (1999–2014) included years that were later than the study period 
in these studies, the discrepancies may be also, partially, be explained by a tendency for a declining incidence 
of registered HMs over time.
In a region-based study, Joneborg et al. found an average incidence of 2.08/1000 deliveries in Stockholm 
County, Sweden for the period 1991–2010, by using all available registries, including a pathology  database5. 
However, the incidence observed may be influenced by the fact that the region studied included the capital 
of Sweden: a higher average maternal age and a higher proportion of women of Asian descent could cause a 
higher incidence in Stockholm than in other parts of  Sweden5. Savage et al. estimated the average incidence in 
England and Wales to 2.17/1000 maternities for the period 1998–200727 and 2.13/1000 maternities for the period 
2000–200934. The average incidence of registered first HMs in Denmark in the period 2000–2009 was 2.04/1000 
deliveries, making the difference between the British and the Danish incidences less obvious.
Apart from the observations in Stockholm county and UK, the average Danish incidence was higher than the 
incidences observed in all other European population-based studies published after 1990 (Table 3): using data 
from clinical registries, average incidences for Sweden, Finland, and Italy of 0.98–1.5/1000  deliveries4,26,35 and 
0.9–1.04/1000 pregnancies have been reported for various periods from 1973 to  200825,36. These incidences are 
even lower than the minimum average incidence in our study estimated after excluding cases with the moderator 
code indicating “suspicion of ”. This may partly be explained by the fact that the completeness of clinical registries 
tend to be lower than the completeness of pathology  registries16. However, even two studies from the Netherlands, 
using data from a national pathology registry, found lower average incidences than we did: 1.34/1000 deliveries 
from 1995 to  200811, and 1.36/1000 deliveries from 1994 to  20136. Thus, although it is possible that the DPR is 
more complete than the registries in many other European countries, we cannot exclude that the incidence of 
HM is higher in Denmark than in other parts of Europe.
Olsen et al.37 reported an average incidence of HM in Denmark of 1.1/1000 pregnancies in 1977–1992 based 
on data from the Danish National Patient Registry and the Danish Cancer Registry, whereas we observed an 
average incidence of 1.23 HM per 1000 pregnancies in 2007–2014. The main explanation for the higher incidence 
observed in our study may be a higher completeness of the DPR compared to the clinical registries used by 
 Olsen16,35. Assuming a completeness of 0.73 of the Danish National Patient Registry relative to the  DPR16, Olsen 
et al. would have estimated the incidence for the period 1977–1992 to be 1.5/1000 pregnancies if they had used 
the DPR. However, we do not know the completeness of the two registries in the period 1977–1992. Furthermore, 
Olsen et al. used data from both the Danish National Patient Registry and the Danish Cancer Registry. Thus, 
the incidence estimated for the two periods should be compared with caution. Other population-based studies 
reported quite varying incidences per pregnancy. Studies from Sweden, Italy, UK, US, South Korea and Japan 
found average incidences of HM of 0.9–2.2/1000 pregnancies in periods from 1975 to  20098,22,23,25,32,34,36.
Ideally, for calculating the incidence of HM, the denominator should represent the population at risk; that is, 
all conceptuses, both those in pregnancies that ended by live- or stillbirth and those in pregnancies that ended 
by induced or spontaneous abortion, including very early miscarriages. Therefore, the incidence per recognized 
pregnancy may be closer to the ideal than the incidence per delivery. However, the number of deliveries can be 
retrieved more accurately than the number of pregnancies.
We observed a higher average incidence of PHM than of NPHM, although we observed a decrease in the 
incidence of PHM over time. Others reported a higher incidence of PHM compared to  CHM8,10,11,27,34. Eysbouts 
et al. found a clear preponderance of PHMs from 1996 to 2010 in the Netherlands, however from 2010, CHMs 
were observed more frequently than  PHMs6. The clinical appearance of PHMs is more subtle than that of 
CHMs and PHMs often remain undiagnosed  sonographically29,38. Thus, the probability that a PHM is not being 
sent for histopathological examination is higher than the probability that a CHM is not being sent. Likewise, 
the histopathological characteristics of a PHM can be inconspicuous and the distinction between non-molar 
hydropic miscarriages and PHMs can be very  difficult1. Likely the true frequency of PHM is higher than the 
frequency of CHM.
In agreement with several other  studies4,11,25,26, we found a high incidence of HM in both adolescent women 
and women at advanced age, supporting the hypothesis that fertilization of an abnormal oocyte is more likely to 
occur in these age  groups39. Consistently with other  reports27,39, we found the association between the incidence 
of HM and maternal age to be more prominent for NPHM than for PHM, supporting that there is a fundamental 
biological difference between CHM and PHM.
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The frequencies of second and third HMs were 40/1976 (2%) and 1/40 (3%), respectively. In other studies 
a similar frequency of second HMs was observed, whereas a higher frequency of third HMs was  observed40–42. 
The facts that the second mole was of the same type as the first mole in the majority of women, and that in the 
woman with three HMs all were NPHMs, are also consistent with the findings reported by  others41,42. While 
most HMs occur sporadically, some women with recurrent HM (that mostly are CHMs), have a rare autosomal 
recessive predisposition to molar  pregnancies43,44. Hence, the frequency of women with repeated HMs, will be 
higher in populations with a high frequency of consanguinity. In Denmark, the frequency of consanguineous 
marriages is low. Possibly this explains the low number of women with more than one recurrent HM in our study.
Conclusion
The incidence of HMs in Denmark may be among the highest in Europe. Unlike the incidence reported from 
most other European studies, the incidence of registered HM in our study is decreasing, especially for PHM. The 
decrease may partly be explained by a diminished fraction of miscarriages subjected to pathological examination.
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